<DOC>
	<DOCNO>NCT01432236</DOCNO>
	<brief_summary>The intent study identify treat fibromyalgia subject comorbid depression receive SSRI ( selective serotonin reuptake inhibitor ) SNRI ( selective norepinephrine reuptake inhibitor ) primarily depression determine whether pregabalin demonstrate improvement relative placebo improve pain associate fibromyalgia .</brief_summary>
	<brief_title>A Phase 3b Multicenter Study Pregabalin Fibromyalgia Subjects Who Have Comorbid Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Men woman race ethnicity least 18 year age . Adult woman men diagnosis fibromyalgia stable depression ( major depressive disorder , depression otherwise specify ( NOS ) , dysthymia ) take antidepressant ( SSRI SNRI ) primarily depression least 3 month . Have fail pregabalin treatment due lack improvement symptom dose great equal 300 mg daily , tolerate pregabalin pregabalin ingredient , participate pregabalin clinical trial . If subject take pregabalin discontinue reason lack improvement intolerance , eligible . Pregabalin use within last 30 day ( prior V1 ) permit . Patients severe unstable depression eligible . Patients type pain condition may make difficult evaluate fibromyalgia symptom eligible Any subject consider risk suicide self harm base investigator judgment and/or detail risk assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pregabalin</keyword>
	<keyword>Lyrica</keyword>
	<keyword>depression</keyword>
</DOC>